Andrew Lo, Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management, sits down with Neil to discuss his application of portfolio theory to address the challenges of funding drug development and how a Netflix subscription model can address the coming crisis in funding high-priced curative therapies approaching the market.

Faizzan Ahmad, Co-Founder and CEO of Cure8bio, sits down with Neil to discuss its growing portfolio of regenerative medicines in development, its hub-and-spoke business model designed to leverage resources and reduce risk, and its push toward curative therapies.

Nathan Hunkapiller, Chief Scientific Officer and Co-Founder of Curve Biosciences, sits down with Neil to discuss liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention.

Drew Titmarsh, Co-Founder and CEO of Dynomics, sits down with Neil to discuss the lack of innovative therapies to treat heart disease, the company’s discovery platform that uses engineered cardiac organoids that function like adult human heart tissue, and how the company is using this to develop precision therapies to address the root causes of heart failure.

Summary David Li , Co-Founder and CEO of Meliora Therapeutics , sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how the platform technology to uncover the true ...

Investors entering the landscape of venture capital are often bombarded with acronyms for terms that can seem foreign. While a general understanding of the concept that the term represents can be understood by context, knowing the complete meaning of these terms can provide powerful insight into better understanding the return profile of an investment and help make better informed investments. In this paper, we hope to elucidate some commonly used acronyms and the concepts behind them in order to make the world of VC more accessible to anyone approaching it.

We are excited to bring you a new episode of "The One Away Show" with Bryan Wish which featured our Founder and CEO, Neil Littman! Here he discussed investing in causes one believes in, being motivated by impacting more people's lives, financial opportunities in the healthcare industry, as well as ...

We're thrilled to share that Bioverge hosted an Ask Me Anything (AMA) session on July 20, 2023, where we dove into the depths of biotech and healthcare venture capital. During the AMA session, our CEO Neil Littman addressed ...

One little girl opened my eyes to the awe-inspiring innovative possibilities emerging in healthcare and biotechnology. Every day we’re seeing profound breakthroughs in biological research that are rapidly transforming our understanding of disease and the human body. Equally exciting are advancements in technology in computing and beyond. In biotech, the ...